---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000283"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:55:24.228481+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "low"
source: SEC EDGAR
---

# Galecto reports $66M cash as of Dec 31, 2022; updates corporate presentation

## Summary
- Cash, cash equivalents, and investments of approx. $66M as of Dec. 31, 2022.
- Updated corporate presentation dated Jan. 2023 furnished as an exhibit; no specific details or material changes described.
- No financial or operational guidance provided beyond the cash balance update.

## SEC filing metadata
- accession: 0000950170-23-000283
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: low
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000095017023000283/0000950170-23-000283-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000095017023000283/glto-20230106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000283
- JSON: https://secwatch.observer/filing/0000950170-23-000283.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000283.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.